Foghorn Therapeutics Inc. (FHTX) Misses Q2 EPS by 9c

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.66), $0.09 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $8.69 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Utah Medical Products (UTMD) Reports Q1 EPS of $1.10
• Byline Bancorp (BY) Tops Q1 EPS by 6c